

AMENDMENTS TO THE SPECIFICATIONIn the Specification

Please replace the paragraph beginning at page 5, line 10, with the following replacement paragraph:

The IGF-2 peptide of the present invention includes the IGF-2 protein of SEQ ID NO:1 or fragment thereof, capable of modulating an immune response. In certain embodiments, the IGF-2 peptide comprises at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 amino acids. In another embodiment, the IGF-2 peptide of the present invention comprises the amino acid sequence GELVDTLQFVCGDRG (SEQ ID NO:2; B<sub>11-25</sub>). In another embodiment, the IGF-2 peptide is an altered peptide ligand (APL). In certain embodiments, the IGF-2 peptide of the present invention is capable of binding to the HLA-D allele of a subject. In one embodiment, the HLA-D allele is HLA-DQ. In another embodiment, the HLA-D allele is HLA-DQ8. In another embodiment, the HLA-DQ allele is HLA-DQ2.

Please replace the paragraph beginning at page 5, line 20, with the following replacement paragraph:

In certain embodiments, the IGF-2 peptide is modified, *e.g.*, altered or varied, in order to increase the stability of the IGF-2 peptide. In another embodiment, the modification of the IGF-2 peptide further enhances the tolerogeneity ~~decreases the low immunogenicity~~ of the IGF-2 peptide. In certain embodiments, the IGF-2 peptide is modified by PEGylation. In other embodiments, the IGF-2 peptide is modified by complexing the IGF-2 peptide with a MHC class II dimer.

Please replace the paragraph beginning at page 7, line 26, with the following replacement paragraph:

As used herein, the term "fragment" means a subset of the conserved amino acid sequence of an IGF-2 peptide that can cause an effect (*e.g.*, induce tolerance, inhibit a Th<sub>1</sub> autoimmune response, induce a Th<sub>2</sub>-mediated immune response and the like) on the immune

system which regulates T cells. The term is intended to include such fragments in conjunction with or combined with additional sequences or moieties, as for example where the peptide is coupled to other amino acid sequences or to a carrier. The terms "fragment" and "peptide" can, therefore, be used interchangeably since a peptide will be the most common fragment of the IGF-2 protein. Reference herein to a "fragment," "portion" or "segment" of an IGF-2 peptide does not mean that the composition must be derived from the intact IGF-2 protein. Such "fragments," "portions" or "segments" can be produced by various means well-known to those skilled in the art, such as, for example, manual or automatic peptide synthesis, various methods of cloning, or enzymatic treatment of a whole IGF-2 protein. In certain embodiments, the IGF-2 peptide comprises the amino acid sequence GELVDTLQFVCGDRG (SEQ ID NO:2). In other embodiments, the IGF-2 peptide comprises at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 amino acids. In certain embodiments, the IGF-2 peptide of the present invention is capable of binding to the HLA-D allele of a subject. In one embodiment, the HLA-D allele is HLA-DQ. In another embodiment, the HLA-D allele is HLA-DQ8. In another embodiment, the HLA-D allele is HLA-DQ2.